Preparation, preliminary pharmacokinetic and brain targeting study of metformin encapsulated W/O/W composite submicron emulsions promoted by borneol.
Borneol
Brain targeting
Composite submicron emulsions
Metformin hydrochloride
Pharmacokinetics
Slow release
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
15 May 2019
15 May 2019
Historique:
received:
13
11
2018
revised:
21
03
2019
accepted:
22
03
2019
pubmed:
28
3
2019
medline:
16
8
2019
entrez:
28
3
2019
Statut:
ppublish
Résumé
Metformin hydrochloride (Met) is the first-line drug to treat type 2 diabetes and has shown high efficiency in reducing Alzheimer's disease in recent studies. Herein, a borneol W/O/W composite submicron emulsion containing Met (B-Met-W/O/W SE) was prepared, expecting longer in-vivo circulation time, better bioavailability and brain targeting of Met drug. In the optimized formulation, the mean droplets size, polydispersity index and encapsulation efficiency of the composite were 386.5 nm, 0.219 and 87.26%, respectively. FTIR analysis confirmed that Met interacted with carriers in B-Met-W/O/W SE. Compared with Met free drug, in-vitro release of Met in B-Met-W/O/W SE delivery system was much slower. In pharmacokinetic studies in rats, the AUC, MRT and t
Identifiants
pubmed: 30914361
pii: S0928-0987(19)30122-8
doi: 10.1016/j.ejps.2019.03.019
pii:
doi:
Substances chimiques
Camphanes
0
Emulsions
0
Hypoglycemic Agents
0
Metformin
9100L32L2N
isoborneol
L88RA8N5EG
Types de publication
Journal Article
Langues
eng
Pagination
160-166Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.